Note: This document contains side effect information about nateglinide. Some dosage forms listed on this page may not apply to the brand name Starlix.
Applies to nateglinide: oral tablet.
Serious side effects of Starlix
Along with its needed effects, nateglinide (the active ingredient contained in Starlix) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking nateglinide:
More common
- Ear congestion
- cough
- difficulty in breathing
- loss of voice
- sneezing
- sore throat
- stuffy or runny nose
Less common
- Chest tightness
- cough producing mucus
- diarrhea
- general discomfort or illness
- shivering
- sweating
- trouble sleeping
- vomiting
Incidence not known
- Anxiety
- blurred vision
- chills
- clay-colored stools
- cold sweats
- coma
- confusion
- cool, pale skin
- dark urine
- depression
- dizziness
- fast heartbeat
- fever
- headache
- increased hunger
- loss of appetite
- nausea
- nervousness
- nightmares
- seizures
- shakiness
- slurred speech
- stomach pain
- unusual tiredness or weakness
- unpleasant breath odor
- vomiting of blood
- yellow eyes or skin
Other side effects of Starlix
Some side effects of nateglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
- Back pain
- dizziness
- joint pain
- muscle aches and pains
incidence not known
- Hives, itching, skin rash
- redness of the skin
For Healthcare Professionals
Applies to nateglinide: oral tablet.
General
The most frequently reported adverse events included upper respiratory tract infections and symptoms of hypoglycemia.[Ref]
Metabolic
Common (1% to 10%): Hypoglycemia
Frequency not reported: Increases in mean uric acid level[Ref]
Hypoglycemia has been reported and has generally been mild and corrected by intake of carbohydrates. In comparative clinical trials, hypoglycemia was reported in 10.4%, 14.5%, 6.9%, 19.8%, and 4.1% in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, and placebo, respectively.
Mean uric acid levels were increased in patient receiving this drug as monotherapy. The difference from placebo in treated patients was 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, respectively. The clinical significance of these findings is unknown.[Ref]
Respiratory
Common (1% to 10%): Upper respiratory tract infection, bronchitis, coughing[Ref]
Hypersensitivity
Postmarketing reports: Hypersensitivity reactions such as rash, itching, and urticaria[Ref]
Gastrointestinal
Common (1% to 10%): Diarrhea, abdominal pain, dyspepsia, nausea
Uncommon (0.1% to 1%): Vomiting[Ref]
Gastrointestinal symptoms, especially diarrhea and nausea, were no more common in patients using this drug in combination with metformin than in patients receiving metformin alone.[Ref]
Hepatic
Postmarketing reports: Elevated liver enzymes, jaundice, cholestatic hepatitis[Ref]
Nervous system
Common (1% to 10%): Dizziness[Ref]
Musculoskeletal
Common (1% to 10%): Back pain, arthropathy[Ref]
Cardiovascular
Frequency not reported: Peripheral edema[Ref]
Peripheral edema was no more common in patients using this drug in combination with rosiglitazone than in patients receiving rosiglitazone alone.[Ref]
Dermatologic
Postmarketing reports: Erythema multiforme[Ref]
Immunologic
Common (1% to 10%): Flu symptoms[Ref]
Other
Common (1% to 10%): Accidental trauma[Ref]
